AsCNP/JSNP/JSCNP 2019

Session information

[AsCNP] Symposium

AsCNP » [AsCNP] Symposium

[AsCNP_S17] Symposium-17
Clinical research of gut-microbiota-brain axis

Fri. Oct 11, 2019 4:30 PM - 6:10 PM Room 6 (401+402)

Organizer / Chair: Chun-Hsin CHEN (Department of Psychiatry, Municipal Wan-Fang Hospital, Taipei Medical University, Taiwan), Co-chair: Katsuji NISHIMURA (Department of Psychiatry, Tokyo Women's Medical University, Japan), Discussant: ‌Hiroaki TOMITA (Department of Psychiatry, Graduate School of Medicine, Tohoku University, Japan)

Background: Accumulating evidence indicates that the gut microbiota can communicate with central nerve system, and thereby influences brain function and behavior, including mood symptoms. Preclinical studies have shown that consumption of probiotics may alter brain functions and reduce anxiety- or depression-like behaviors. Objective: The symposium aims to demonstrate some evidence of relationships between mood symptoms and microbiota, which may be significantly affected by diet or probiotics, in diverse subjects. First, Dr Okubo will report the association of fear of cancer recurrence (FCR) with omega-3 PUFAs and gut microbiota among breast cancer survivors. FCR among breast cancer survivors especially with chemotherapy history could be controlled by prudent dietary modification considering PUFAs and gut microbiota. Nutritional intervention considering PUFAs and probiotics to alleviate FCR will be proposed in the symposium. Second, Dr Kuo will report the comparisons of consumption of nitrated cured meat and composition of microbiota between patients with mood disorder and healthy control. In addition, peripheral gene expression patterns in patients with bipolar disorder during acute versus remission status will be evaluated. Finally, potential relationships between microbiota targets, nitrated meat consumption, and gene expression in human samples will be explored. Third, Dr Chen will review consumptions of probiotic to alleviate depressive symptoms in different kinds of participants and report meta-analysis of these human studies. Finally, a pilot study augmenting Lactobacillus plantarum PS128 in patients with major depressive disorder and stabilized antidepressant treatment will be reported.